Becker's ASC

Are Multiple-Dose Vials as Safe as Single-Dose Vials If Drawn With Aseptic Technique: Q&A With Dr. Clifford Gevirtz

The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
Seeking Alpha

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
Monthly Prescribing Reference

Biweekly Dosing Approved for Tecvayli in Relapsed/Refractory Multiple Myeloma

The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...
Nasdaq

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
Nasdaq

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...